Get started

Stockstowatch

$JFIN appear to be rising on news or speculation regarding NFTsShares of $JFIN appear to be rising on news or speculation regarding NFTs. For those of you that don't know, NFTs are digital files such as art, video, audio, and other files stored on blockchain, which is the digital ledger technology that powers cryptocurrencies like Bitcoin. Some NFTs have already sold for millions of dollars. Jiayin appear to be linked to speculation that the company may eventually jump into the NFT space. Jiayin is an online individual loan marketplace that seeks to reach underserved customers in China. However, recent buzz on Twitter has people saying the company could potentially get into the NFT space, although there is no real news pointing to that right now. The hype and potential around NFT is certainly at an all-time high and eerily reminiscent of when cryptocurrencies, which are also powered by blockchain, first gained mass popularity several years ago. I would advise caution on anything related to NFTs. While they certainly have taken off in recent months, we are still in very days where the market for these assets will likely remain extremely volatile for quite some time. www.fool.com
NASDAQ:JFIN
by AlenCiken
Is This Volume Any Indicator Of A New Trend?MRKR has been a sleeper all year. No major high-volume days and nothing really to write home about. But it managed to pull off a bigger move earlier on. Now that the gap has filled from the drop a few weeks ago & they secured funds, what will this mean for the company's next steps? "An onslaught of Form 4s showed hand fulls of investors and insiders participating in the recent offering. The company raised the money to fund its Phase 2 trial of MT-401 in acute myeloid leukemia. Marker also plans to develop MultiTAA therapies into clinical trials in other indications and conduct manufacturing activities, among other things. In addition to this, analysts have also weighed in recently. Cantor Fitzgerald initiated coverage on Marker this month. The firm started MRKR at Overweight and gave a price target of $6." Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
NASDAQ:MRKR
by PennyStocks101
Back In The Channel AgainMNKD is back in that Fib channel between the .5 and .382 levels. This was a previous channel earlier in the year. Now that the financing deal is done, will it finally see a prolonged uptrend without much interruption? " However, with fresh capital in hand, the company aims at advancing its current pipeline. This includes a Phase 3 clinical trial of its Afrezza inhaled insulin product in pediatric subjects. MannKind also explained that it wants to further the development of product candidates in its pipeline. The company may also use a portion of the proceeds for acquisitions or strategic investments in complementary businesses or technologies. Even with the pullback, analysts seem to remain bullish on the company. SVB Leerink most recently adjusted its price target on the stock. It had previously issued a $3 target but upped it to $5. The firm also carries an Outperform rating on the stock. " Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
NASDAQ:MNKD
by PennyStocks101
SELB Back In High TrafficSELB is back in the upper area of its high-traffic support/resistance from several times prior. Most recently, it saw this act as support in February. But it wasn't able to sustain the level. Anyway, it's back at this but in this case, the level has acted as a potential resistance (for now). It's gonna be interesting to see what happens next. Selecta seems to have benefited from a bullish outlook discussed by the company in its last corporate update. “We are very pleased by the continued progress of our gene therapy program. In collaboration with AskBio, our lead program in methylmalonic acidemia, is on track to enter the clinic in the second quarter of this year, and we expect initial data by the end of the year,” said Carsten Brunn, Ph.D., president, and chief executive officer of Selecta. “A key objective of 2021 will be to generate human data in our gene therapy programs and to continue to build our extensive pipeline in gene therapies, enzyme therapies–with an expected IND filing by the end of the year in IgA nephropathy–and autoimmune diseases, as we work to deliver on our mission to leverage our pioneering ImmTOR platform to improve the lives of patients and their families.” Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
S
by PennyStocks101
Is OPK Fibbin'?OPK back at the .236 fib line, which has been a clear area of support/resistance. The question is, will the speculation on its testing company end up giving the boost needed to push back above the $5 mark or is this truly a "fib" and OPK falls back down heading into the rest of March? "Ongoing pressure from an activist investor to offload its BioReference unit has also become a source of speculation. This stemmed from recent M&A action within the diagnostics space earlier this month. Needless to say, the recent action in the stock has continued supporting some analysts’ bullish stances on the company. Most recently, Barrington Research boosted its price target to $8 from $7 and maintained its Outperform rating." Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
NASDAQ:OPK
by PennyStocks101
$TKAT surged yesterday due to hype in NFT art?The Hong Kong-based online art trading platform rose prompted by increased attention from social media amid frenzy surrounding non-fungible tokens. NFTs are akin to a digital certificate of ownership. Takung provides collectors a way to jointly own Asian and other fine arts including paintings, calligraphies, jewelry, and precious gems, according to its website. The hype in NFT art ranging from sneakers to memes have been in the focus of late and a piece from Beeple — “The First 5000 Days” — commanded price tags of millions of dollars. Tesla Inc TSLA CEO Elon Musk also jumped on the bandwagon and put an NFT song — on NFTs — for sale, which the artist Beeple offered to purchase for $69 million, but later changed his mind. www.benzinga.com
T
by AlenCiken
$LKCOLuokung Technology Corp., through its subsidiaries, provides location-based services and mobile application products for long distance travelers in the People's Republic of China. It offers Luokuang mobile application, a content and service distribution platform that provides content and services, such as information, entertainment, travel, e-commerce, online to offline, advertisement, and other marketing features. The company also offers software development kits and application-programming interfaces, which provide spatial-temporal big data analysis and customized map to software and mobile application developers; and spatial temporal indexing cloud service, a data-level virtualization technology. In addition, it offers information SuperEngine that includes the server engine, which enables to store, manage, and index the spatial temporal big data on the server side; and Web graphics image engine that supports transmission of graphics images, as well as display and edge computing for multi-terminal and cross-platform. Further, the company provides spatial temporal cloud platform that offers cloud services, including data storage, data resource, and platform support services, as well as supports users to aggregate multi-source spatial data, map services, and Internet of Things streaming data. Luokung Technology Corp. has a strategic partnership with Jiangsu Dianyu Information Technology Co., Ltd. to expand mobile commercial big data services in the 5G era. Luokung Technology Corp. is headquartered in Beijing, China.
NASDAQ:LKCOLong
by BADQOMOCAWGOWLD
Bayer pharmaceutical stock long term buy opportunityBayer stock is a life science company trading on the German stock exchanges with the symbol BAYN. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and speciality therapeutics, especially in the areas of cardiology, oncology, gynaecology, haematology and ophthalmology, as well as radio-pharmacology and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter. Bayer AG stock is a German company trading in the German Stock Exchange. It is one of the biggest and most important pharmaceutical companies in the world. I doubt that you’ve never heard from Bayer AG, because its products range from the famous Aspirin to even “more popular” Viagra 🙂 Now, I believe you are probably smiling and remembering this company 🙂 Before starting to write this blog post on Bayer, I googled the company name to try and find some extra information I could add, that would either support or negate the strong rally we are expecting on this particular pharmaceutical German stock.
XETR:BAYNLong
by AlfonsoMoreno
VISL chillin in historic channel, where will it break?Will we finally see VISL break up and out of this channel? It's been a relatively consistent area of support/resistance. With several potential catalysts to consider here (5G, general broadcast, telecom, esports) it will be interesting to see if these tailwinds act as a stronger catalyst. "While it will likely focus on some as it relates to 5G penny stocks, esports could be another facet to consider. If you sift through some of the company’s blog posts, you’ll notice that Vislink’s partner, NEP Sweden, covered the “BLAST Premier Spring Series” last year. This is an international esports event featuring the world’s top esports teams competing in the first-person shooter game series Counter-Strike...NEP filmed the event using Vislink’s HCAMs feeding into a ULRX-LD all controlled by Vislink’s FocalPoint Camera Control System. While no further esports-related updates have come about from the company, a surge in the excitement surrounding esports could be something to take note of." Quote Source: Hot Penny Stocks To Buy Now? 4 To Watch After Roblox (RBLX) IPO
NASDAQ:VISL
by PennyStocks101
BIOL Back In The Channel AgainIt's almost exhausting watching BIOL do this every time...jump, fall, jump, fall, all right back to this channel. There's an interim gap to fill from a few weeks back but still many other levels to consider IF it can break back above and out of this channel. I think volume will be an indicator to watch in consideration of whether or not this can happen. Because dental procedures have resumed to most of their pre-covid levels, many investors are bullish on the future of Biolase. While it is affected by the pandemic, the company is working to build new strategies. This goes hand in hand with its need to continue innovating and receiving new patents. With all of this in mind, is BIOL a penny stock to watch? Quote Source: 5 Biotech Penny Stocks On Robinhood To Watch In March 2021
B
by PennyStocks101
3
SYN Still Trying To Fill The GapThere's still a pretty big gap to fill from a few years ago but again, with a lot of biotech gaining recently, small caps could be back on the menu. After Maxim Group upgraded SYN from a hold to a buy, shares of the biotech company dramatically increased. In addition to this, Maxim Group analysts gave a price target for SYN of $2.50. This represents a 10% or so gain from where it was before the rating. At the end of Friday, March 12th, SYN stock had shot up by over 29% to $0.92...CEO Steven Shallcross stated that “we are more encouraged than ever by this outlook for the business as we have made important progress during the fourth quarter advancing and demonstrating the significant value of our clinical development programs. With a number of upcoming catalysts later this year, we believe there is potential to continue to deliver significant value for our shareholders.” Quote Source: 5 Biotech Penny Stocks On Robinhood To Watch In March 2021
S
by PennyStocks101
1
Back At Historical S/R Level On ISRISR has been something of a sight in this market. Now, after pulling in and settling down a bit, it's back at the historic support/resistance level. With momentum acting as a tailwind in biotech stocks, overall, I'll be interested to see if it can get back above this level in more of a "calm fashion" haha. While fewer surgeries occurred last year due to covid, IsoRay has managed to work around this, building its brachytherapy use cases along the way. CEO Lori Woods stated that “we are very pleased that we have been able to continue to make progress this quarter despite the ongoing challenges that the Covid-19 pandemic has presented. Amongst the highlights has been our continued success in expanding adoption of Celsium-131 in our core prostate market.” Quote Source: 5 Biotech Penny Stocks On Robinhood To Watch In March 2021
I
by PennyStocks101